二十碳五烯酸乙酯减少血运重建:REDUCE-IT血运重建分析
REDUCE-IT试验随机分配8179例他汀治疗下甘油三酯升高(135-499 mg/dL)且心血管风险增高的患者,接受二十碳五烯酸乙酯4 g/d或安慰剂,中位随访4.9年。预设分析显示,二十碳五烯酸乙酯显著减少首次及后续冠状动脉血运重建,并显著降低经皮冠状动脉介入和冠状动脉旁路移植术风险。
要点
- 二十碳五烯酸乙酯减少首次血运重建(9.2% vs 13.3%,HR 0.66)。
- 总血运重建率比0.64,择期、紧急和急诊血运重建均减少。
- 显著降低PCI(HR 0.68)和CABG(HR 0.61)风险。
核心结论
- 在他汀治疗的甘油三酯升高且心血管风险增高的患者中,二十碳五烯酸乙酯减少首次和后续冠状动脉血运重建需求。
- 二十碳五烯酸乙酯是首个在盲法随机试验中显示减少冠状动脉旁路移植术的非低密度脂蛋白降低治疗。
研究设计与样本
- REDUCE-IT为多中心、双盲、安慰剂对照试验,随机分配他汀治疗的甘油三酯135-499 mg/dL、低密度脂蛋白41-100 mg/dL且已确诊心血管疾病或糖尿病加其他危险因素的患者。
- 共8179例患者随机接受二十碳五烯酸乙酯4 g/d或安慰剂,中位随访4.9年;预设分析评估所有冠状动脉血运重建、复发性血运重建及血运重建亚型。
主要发现
- 首次血运重建率二十碳五烯酸乙酯组9.2%(22.5/1000患者年)vs 安慰剂组13.3%(33.7/1000患者年),HR 0.66(95%CI 0.58-0.76),P<0.0001,4.9年需治疗人数=24。
- 总(首次和后续)血运重建负二项率比0.64(95%CI 0.56-0.74),P<0.0001;择期、紧急和急诊血运重建均观察到相似减少。
- 二十碳五烯酸乙酯显著减少经皮冠状动脉介入(HR 0.68,95%CI 0.59-0.79,P<0.0001)和冠状动脉旁路移植术(HR 0.61,95%CI 0.45-0.81,P=0.0005)。
关键数值与推荐
- 甘油三酯入选范围135-499 mg/dL,低密度脂蛋白41-100 mg/dL。
- 二十碳五烯酸乙酯剂量4 g/d,中位随访4.9年。
- 首次血运重建HR 0.66(95%CI 0.58-0.76),P<0.0001,需治疗人数=24。
- 总血运重建率比0.64(95%CI 0.56-0.74),P<0.0001。
- PCI的HR 0.68(95%CI 0.59-0.79),P<0.0001;CABG的HR 0.61(95%CI 0.45-0.81),P=0.0005。
临床怎么用
- 对于他汀治疗后甘油三酯仍升高(135-499 mg/dL)且低密度脂蛋白控制(41-100 mg/dL)的高心血管风险患者,可考虑加用二十碳五烯酸乙酯4 g/d以降低冠状动脉血运重建风险。
- 治疗决策需结合患者心血管风险、甘油三酯水平及耐受性,并关注二十碳五烯酸乙酯对PCI和CABG需求的减少作用。
局限性
- 分析为REDUCE-IT试验的预设分析,非独立研究。
- 随访中位4.9年,长期效果未明。
- 结果基于特定入选标准(甘油三酯135-499 mg/dL,LDL-C 41-100 mg/dL)人群,外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with elevated triglycerides despite statin therapy have increased risk for ischemic events, including coronary revascularizations. METHODS: REDUCE-IT (The Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial), a multicenter, double-blind, placebo-controlled trial, randomly assigned statin-treated patients with elevated triglycerides (135-499 mg/dL), controlled low-density lipoprotein (41-100 mg/dL), and either established cardiovascular disease or diabetes plus other risk factors to receive icosapent ethyl 4 g/d or placebo. The primary and key secondary composite end points were significantly reduced. Prespecified analyses examined all coronary revascularizations, recurrent revascularizations, and revascularization subtypes. RESULTS: A total of 8179 randomly assigned patients were followed for 4.9 years (median). First revascularizations were reduced to 9.2% (22.5/1000 patient-years) with icosapent ethyl versus 13.3% (33.7/1000 patient-years) with placebo (hazard ratio, 0.66 [95% CI, 0.58-0.76]; P<0.0001; number needed to treat for 4.9 years=24); similar reductions were observed in total (first and subsequent) revascularizations (negative binomial rate ratio, 0.64 [95% CI, 0.56-0.74]; P<0.0001), and across elective, urgent, and emergent revascularizations. Icosapent ethyl significantly reduced percutaneous coronary intervention (hazard ratio, 0.68 [95% CI, 0.59-0.79]; P<0.0001) and coronary artery bypass grafting (hazard ratio, 0.61 [95% CI, 0.45-0.81]; P=0.0005). CONCLUSIONS: Icosapent ethyl reduced the need for first and subsequent coronary revascularizations in statin-treated patients with elevated triglycerides and increased cardiovascular risk. To our knowledge, icosapent ethyl is the first non-low-density lipoprotein-lowering treatment that has been shown to reduce coronary artery bypass grafting in a blinded, randomized trial. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01492361.
引用
- Peterson BE, Bhatt DL, Steg PG, et al. Reduction in Revascularization With Icosapent Ethyl: Insights From REDUCE-IT Revascularization Analyses. Circulation. 2020. PMID: 33148016. doi:10.1161/CIRCULATIONAHA.120.050276
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。